See more : UNIRITA Inc. (3800.T) Income Statement Analysis – Financial Results
Complete financial analysis of Protect Pharmaceutical Corporation (PRTT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Protect Pharmaceutical Corporation, a leading company in the Conglomerates industry within the Industrials sector.
You may be interested
- Fidelity National Information Services, Inc. (FIS) Income Statement Analysis – Financial Results
- Zhejiang Jiahua Energy Chemical Industry Co.,Ltd. (600273.SS) Income Statement Analysis – Financial Results
- Ichinen Holdings Co., Ltd. (9619.T) Income Statement Analysis – Financial Results
- Asia Holdings Co., Ltd. (002030.KS) Income Statement Analysis – Financial Results
- Gujarat Ambuja Exports Limited (GAEL.NS) Income Statement Analysis – Financial Results
Protect Pharmaceutical Corporation (PRTT)
About Protect Pharmaceutical Corporation
Protect Pharmaceutical Corporation primarily focuses on crop farming and agricultural businesses. It acquires the Can Noguera property located in Selva Girona region in Spain. Its property consists of 60 hectares of arable land, 390 hectares of forests, 6 mineral and freshwater wells, and 3000 square meters of built properties. The company was formerly known as Pro-Tect, Inc. and changed its name to Protect Pharmaceutical Corporation in March 2010. Protect Pharmaceutical Corporation was founded in 1987 and is based in Las Vegas, Nevada.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 136.16M | 81.80M | 78.79M | 5.94M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 62.85M | 40.22M | 34.43M | 78.26K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 73.31M | 41.58M | 44.37M | 5.86M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 53.84% | 50.83% | 56.31% | 98.68% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 4.79M | 1.75M | 1.91M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 123.19K | 1.25M | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 115.40K | 41.71K | 30.03K | 30.85K | 23.94K | 554.30K | 0.00 | 392.58K | 2.15K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 5.38M | 0.00 |
| SG&A | 20.98M | 14.57M | 14.58M | 42.28K | 1.87K | 115.40K | 41.71K | 30.03K | 30.85K | 23.94K | 554.30K | 786.92K | 5.77M | 2.15K |
| Other Expenses | 0.00 | 0.00 | 0.00 | -5.83K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 25.77M | 16.32M | 16.49M | 48.11K | 1.87K | 115.40K | 41.71K | 30.03K | 30.85K | 23.94K | 554.30K | 910.11K | 7.03M | 2.15K |
| Cost & Expenses | 88.62M | 56.54M | 50.92M | 126.37K | 1.87K | 115.40K | 41.71K | 30.03K | 30.85K | 23.94K | 554.30K | 910.11K | 7.03M | 2.15K |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 1.38K | 0.00 | 7.21K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 167.90K | 228.49K | 236.56K | 206.30K | 171.86K | 115.40 | 41.71 | 605.44K | -488.99K | 23.94 | 0.00 | -640.00K | 0.00 | 0.00 |
| EBITDA | 47.54M | 25.26M | 27.88M | 5.81M | -1.87K | -115.40K | -41.71K | 575.41K | -519.84K | -23.94K | -554.30K | -270.11K | -7.03M | -2.15K |
| EBITDA Ratio | 34.92% | 30.88% | 35.38% | 97.87% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | 47.54M | 25.26M | 27.88M | 5.81M | -1.87K | -115.40K | -41.71K | -30.03K | -30.85K | -23.94K | -554.30K | -910.11K | -7.03M | -2.15K |
| Operating Income Ratio | 34.92% | 30.88% | 35.38% | 97.87% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 0.00 | 0.00 | 0.00 | -1.37K | -3.00 | -7.21K | 0.00 | -605.44K | 488.99K | 0.00 | 0.00 | 640.00K | 0.00 | 0.00 |
| Income Before Tax | 47.54M | 25.26M | 27.88M | 5.81M | -1.87K | -122.61K | -41.71K | -635.46K | 458.15K | -23.94K | -554.30K | -270.11K | 0.00 | 0.00 |
| Income Before Tax Ratio | 34.92% | 30.88% | 35.38% | 97.85% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 1.63M | 2.82M | 7.67M | -206.30K | -171.86K | -115.40 | -38.71 | 0.00 | 0.00 | -23.94 | 0.00 | 0.00 | 7.03M | 2.15K |
| Net Income | 45.91M | 22.44M | 20.21M | 5.81M | -1.87K | -122.61K | -41.71K | -635.46K | 458.15K | -23.94K | -554.30K | -270.11K | -7.03M | -2.15K |
| Net Income Ratio | 33.72% | 27.44% | 25.65% | 97.85% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | 0.80 | 0.43 | 0.36 | 0.11 | 0.00 | -0.11 | -0.04 | -1.44 | 8.48 | -0.54 | -12.44 | -6.16 | -172.65 | -0.06 |
| EPS Diluted | 0.80 | 0.43 | 0.36 | 0.11 | 0.00 | -0.10 | -0.04 | -1.44 | 8.48 | -0.54 | -12.44 | -6.16 | -172.65 | -0.06 |
| Weighted Avg Shares Out | 57.45M | 52.78M | 56.25M | 54.95M | 54.95M | 1.11M | 1.11M | 442.17K | 54.05K | 44.57K | 44.57K | 43.86K | 40.70K | 33.16K |
| Weighted Avg Shares Out (Dil) | 57.45M | 52.78M | 56.25M | 54.95M | 54.95M | 1.20M | 1.11M | 442.17K | 54.05K | 44.57K | 44.57K | 43.86K | 40.70K | 33.16K |
Protect Pharmaceutical Corp. Announces that KARINCA Logistics Merger Will Not Proceed
ANKARA, Turkey, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Protect Pharmaceutical Corp. (OTC: PRTT) (“Company”) and Atlantic Logistics announce there will be no merger with KARINCA Logistics.
Protect Pharmaceutical Corp. (PRTT) Announces New CEO and New Director; Moves to Finalize the Karinca Logistics Merger
ANKARA, Turkey, Aug. 15, 2024 (GLOBE NEWSWIRE) -- Protect Pharmaceutical Corp. (OTC: PRTT) ("Company") announces the appointment of a new CEO, restructuring of the Board of Directors, and looks to finalize the merger agreement with Karinca Logistics - www.karincalogistics.com ....
Protect Pharmaceutical Corp. Issues Corporate Update
ANKARA, Turkey, July 01, 2024 (GLOBE NEWSWIRE) -- Protect Pharmaceutical Corp.'s (OTC: PRTT) (“Company”) President, Ali Yildiz, provides its shareholders with the following informational update: "July 1, 2024 Dear Shareholders: The Company's PCAOB audit for the fiscal year of 2023...
Protect Pharmaceutical Corp.'s President, Ali Yildiz, Issues a Letter to Shareholders
ISTANBUL, Turkey, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Protect Pharmaceutical Corp.'s (OTC: PRTT) President, Ali Yildiz, publishes his February 2024 corporate update letter to Company Shareholders as follows: "February 5, 2024 Dear Shareholders: Management announces that it has finalized its...
Ali Yildiz, President of Protect Pharmaceutical Corp., Issues Letter to Shareholders
ISTANBUL, Turkey, Jan. 09, 2024 (GLOBE NEWSWIRE) -- Protect Pharmaceutical Corp.'s (OTC: PRTT) President, Ali Yildiz, publishes a letter to Company Shareholders as follows: “Dear Shareholders of Protect Pharmaceutical Corp.: We have continued working with respect to finalizing our PCAOB...
Ali Yildiz December 29, 2023 Letter to the Shareholders of Protect Pharmaceutical Corp.
Istanbul, Turkey, Dec. 29, 2023 (GLOBE NEWSWIRE) -- Protect Pharmaceutical Corp. “OTC:(PRTT)” Ali Yildiz Addresses shareholders of the company.
Ali Yildiz December 22, 2023 Letter to the Shareholders of Protect Pharmaceutical Corp.
Istanbul, Turkey, Dec. 22, 2023 (GLOBE NEWSWIRE) -- Protect Pharmaceutical Corp. “OTC:(PRTT)” Ali Yildiz Addresses shareholders of the company.
Protect Pharmaceutical Corp. CEO Provides Shareholder Update
Istanbul, Turkey, Dec. 15, 2023 (GLOBE NEWSWIRE) -- Protect Pharmaceutical Corp. “OTC:(PRTT)” Protect Pharmaceutical Corp. CEO Ali Yildiz Provides Shareholder Update.
Protect Pharmaceutical Corp. Acquires Bosfor Export
Istanbul, Turkey, Nov. 24, 2023 (GLOBE NEWSWIRE) -- Protect Pharmaceutical Corp. “OTC: PRTT” is pleased to announce the acquisition of Bosfor Export. This strategic move has been financed through the issuance of 2,000,000 restricted shares, representing 100% ownership of Bosfor...
Protect Pharmaceutical Corp. CEO Provides Shareholder Update
Istanbul, Turkey, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Protect Pharmaceutical Corp. “OTC:(PRTT)” Protect Pharmaceutical Corp. CEO Ali Yildiz Provides Shareholder Update.
Source: https://incomestatements.info
Category: Stock Reports